Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4

Cancer Lett. 2006 Apr 28;235(2):229-38. doi: 10.1016/j.canlet.2005.04.012. Epub 2005 May 31.


We investigated the anti CT26 tumour effect of dendritic cell based vaccination with the MuLV gp70 envelope protein-derived peptides AH1 and p320-333. Vaccination lead to generation of AH1 specific cytotoxic lymphocytes (CTL) and some decrease in tumour growth of simultaneously inoculated CT26 cells. After combination with an antibody against VEGF receptor 2 (DC101), a significant increase in survival of the tumour cell recipients was observed. Also, monotherapy with an antibody against CTLA-4 (9H10), led to approximately 100% survival of tumour cell recipients. However, effective treatment of mice with already established tumours was only obtained after combination of vaccination, DC101 and 9H10 treatment in which setting 80% of the mice rejected their tumours.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, CD
  • Antigens, Differentiation / immunology*
  • CTLA-4 Antigen
  • Colonic Neoplasms / immunology
  • Colonic Neoplasms / therapy*
  • Combined Modality Therapy
  • Dendritic Cells / immunology*
  • Epitopes, T-Lymphocyte
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Transplantation
  • T-Lymphocytes, Cytotoxic / immunology
  • Vaccination
  • Vaccines / immunology*
  • Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*


  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • Epitopes, T-Lymphocyte
  • Vaccines
  • Vascular Endothelial Growth Factor Receptor-2